PV-10 Shows Promise as Novel STING-Pathway Vaccine Adjuvant in University of Calgary Research
Key Insights
University of Calgary researchers demonstrated that PV-10, Provectus Biopharmaceuticals (search)' rose bengal sodium formulation, activates the STING (search) immune pathway to enhance hepatitis B (search) vaccine responses.
The preclinical study showed PV-10 stabilizes STING (search) dimerization, upregulates pro-inflammatory cytokines, and significantly boosts IFN-gamma (search) secretion by antigen-primed T cells.
This novel mechanism positions PV-10 as a potential safer alternative to traditional vaccine adjuvants like aluminum salts, targeting the $2 billion adjuvant market projected by 2030.
Provectus Biopharmaceuticals (search) announced the publication of independent preclinical research demonstrating that PV-10, a formulation of rose bengal sodium, activates the body's natural STING (search) (stimulator of interferon genes) immune pathway to enhance vaccine responses. The study, conducted by Dr. Aru Narendran and colleagues at the University of Calgary's Cumming School of Medicine, was published in Human Vaccines & Immunotherapeutics.
The research, titled "PV-10 as New Adjuvant Enhances Immune Responses in Hepatitis B (search) Vaccination Through STING (search) Pathway," reveals a novel mechanism that could position PV-10 as a differentiated alternative to widely used vaccine adjuvants such as aluminum salts, emulsions, saponins, and nucleic acid-based fragments, many of which face questions around safety, reactogenicity, and long-term impact.
STING Pathway Activation Mechanism
Dr. Narendran and colleagues' research demonstrated that PV-10 functions through three key mechanisms:
- Stabilizes STING dimerization, a critical step in activating the body's innate immunity
- Upregulates pro-inflammatory cytokines and chemokines essential for the immune system's adaptive responses
- Significantly boosts IFN-gamma secretion by antigen-primed T cells
These findings indicate PV-10's potential to rescue immune non-responders—individuals who fail to mount protection with current vaccines—and serve as an immune system activator across infectious disease, oncology, and pandemic preparedness applications.
Clinical and Commercial Implications
"We believe this research validates PV-10 as more than a cancer drug for injectable solid tumors, it can be a platform immune enhancer," said Dominic Rodrigues, President and Vice Chair of the Board of Directors of Provectus. "By working through the natural pathway of STING (search) that cells already use to recognize threats to our bodies, PV-10 offers the chance to potentially strengthen immunity without relying on historical or controversial vaccine additives."
The research suggests particular promise for addressing vaccine non-response, which affects approximately 10% of healthy individuals who fail to respond to existing vaccines such as hepatitis B (search). For patients, this could translate into safer, more effective protection where current options fail.
Market Potential
The vaccine adjuvant market is projected to exceed $2 billion annually by 2030. PV-10's differentiated safety profile and mechanism create potential opportunities across multiple sectors:
Infectious Disease Vaccines: Global vaccine sales are expected to surpass $70 billion by 2030, with a $1 billion-plus adjuvant subset. PV-10 could offer a safer alternative for vaccine non-responders.
Oncology Vaccines: A market projected to exceed $10 billion by 2032, where effective immune activation is critical. PV-10's STING (search)-mediated activity could complement immune checkpoint inhibitors that generate more than $40 billion annually but require stronger T-cell priming to expand durable responses.
Preparedness Programs: Governmental and non-governmental organizations invest billions annually in stockpiling epidemic and pandemic response tools, with safer, more effective vaccine adjuvants representing a high-priority unmet need.
The research positions PV-10 at the convergence of multi-billion-dollar markets in infectious disease, oncology, and immune system health, potentially serving underserved populations including older adults, immunocompromised individuals, and those who never achieve immunity with existing formulations.